Document is current
Any future updates will be listed below
-
Authors
Corona, Magdalena
Ip, Andrew https://orcid.org/0000-0003-0456-5618
Brown, Samantha https://orcid.org/0000-0001-5352-974X
Luna, Alejandro
Khatib, Hazim
Flynn, Jessica R.
Devlin, Sean M.
Landego, Ivan
Cassanello, Giulio
Rejeski, Kai https://orcid.org/0000-0003-3905-0251
Zuckerman, Tsila https://orcid.org/0000-0002-6204-977X
Dahi, Parastoo B. https://orcid.org/0000-0002-0794-3226
Scordo, Michael
Lin, Richard J. https://orcid.org/0000-0002-0834-7880
Kabat, Maciej
Luttwak, Efrat
Pavkovic, Emma
Palomba, M. Lia
Park, Jae
Salles, Gilles https://orcid.org/0000-0002-9541-8666
Schoder, Heiko
Leithner, Doris
Leslie, Lori A.
Perales, Miguel-Angel https://orcid.org/0000-0002-5910-4571
Beyar-Katz, Ofrat
Shah, Gunjan L.
Shouval, Roni https://orcid.org/0000-0001-9827-8032
-
Funding
Funding for this research was provided by:
Long Island Sounds, Swim Across America
Alfonso Martin Escudero Foundation
FEHH/Gilead
Associazione Italiana Contro le Leucemie - Linfomi e Mieloma
- License Information
-
More Information
Article History
Received: 2 October 2024
Revised: 16 December 2024
Accepted: 23 January 2025
First Online: 1 February 2025
Competing interests
: Perales reports honoraria from Adicet, Allogene, Allovir, Caribou Biosciences, Celgene, Bristol-Myers Squibb, Equilium, Exevir, ImmPACT Bio, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Sanofi, Syncopation, VectivBio AG, and Vor Biopharma. He serves on DSMBs for Cidara Therapeutics and Sellas Life Sciences, and the scientific advisory board of NexImmune. He has ownership interests in NexImmune, Omeros, and OrcaBio. He has received institutional research support for clinical trials from Allogene, Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis. Lori Leslie reports honoraria/consulting/speaker bureau from Gilead/Kite, SeaGen, ADC Therapeutics, Celgene/BMS, Janssen/J&J, Pharmacyclics, Beigene, Abbvie, Genmab, AstraZeneca, TG Therapeutics, Epizyme, Karyopharm, Merck, Eli Lily. Gunjan Shah has research funding to the institution from Janssen, Amgen, BMS, Beyond Spring, and GPCR, and is on the DSMB for ArcellX. K.R. Kite/Gilead: Research Funding, Consultancy, Honoraria, and travel support; Novartis: Honoraria; BMS/Celgene: Consultancy, Honoraria; Pierre-Fabre: travel support. Lori A Leslie reports honoraria/consulting/speaker bureau from Gilead/Kite, SeaGen, ADC Therapeutics, Celgene/BMS, Janssen/J&J, Pharmacyclics, Beigene, Abbvie, Genmab, AstraZeneca, TG Therapeutics, Epizyme, Karyopharm, Merck, Eli Lily. Michael Scordo has served as a paid consultant for McKinsey & Company, Angiocrine Bioscience, and Omeros; has received research funding from Angiocrine Bioscience and Omeros; has served on ad hoc advisory boards for Kite Pharma; and has received honoraria from i3Health and Medscape for CME related activity. Dr. Sergio A. Giralt is a consultant for and receives research funding from Amgen, Actinium, Celgene, Johnson & Johnson, and Takeda and is a consultant for Jazz Pharmaceuticals, Novartis, Kite Pharma, and Spectrum Pharmaceuticals. Samantha Brown receives salary support from AACR Project GENIE Biopharma Collaborative. The remaining authors declare no competing interests.
